Drug profile · INN
sitagliptin phosphate
SITAGLIPTIN PHOSPHATE
sitagliptin phosphate (SITAGLIPTIN PHOSPHATE) is a dipeptidyl peptidase iv inhibitor. Associated with Teva Pharma GmbH. Route of administration: film coated. Current US regulatory status: approved.
Drug details — sitagliptin phosphate
- US status
- approved
- Class
- —
- Route
- FILM COATED
- Patents
- 2
- Programs
- 2
- Data quality
- 0.89
Quick answer
sitagliptin phosphate (SITAGLIPTIN PHOSPHATE) is a dipeptidyl peptidase iv inhibitor. Associated with Teva Pharma GmbH. Route of administration: film coated. Current US regulatory status: approved.
Key facts
Mechanism of action
Dipeptidyl peptidase IV inhibitor
Primary target: Dipeptidyl peptidase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is sitagliptin phosphate?
sitagliptin phosphate (SITAGLIPTIN PHOSPHATE) is a dipeptidyl peptidase iv inhibitor. Associated with Teva Pharma GmbH. Route of administration: film coated. Current US regulatory status: approved.
What is the brand name for sitagliptin phosphate?
SITAGLIPTIN PHOSPHATE is a marketed brand name for sitagliptin phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sitagliptin phosphate?
sitagliptin phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.